First Quadrant’s Arbutus Biopharma ABUS Stock Holding History

First Quadrant’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-75,700	Closed	-$294K	–	138
2021 Q4	$294K	Buy	+75,700	New	+$294K	0.03%	304

Other funds holding ABUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

First Quadrant's ABUS Position: Q1 2022 in Review

First Quadrant sold out of Arbutus Biopharma (ABUS) in Q1 2022, closing a stake of 75,700 shares — an estimated $294K sold.

First Quadrant first reported a position in ABUS in Q4 2021 and held it in 1 quarter. The position peaked at $294K in Q4 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2022.

First Quadrant reported no remaining Arbutus Biopharma position as of Q1 2022 after selling out during the quarter.
First Quadrant sold 75,700 Arbutus Biopharma shares in Q1 2022, an estimated $294K.
First Quadrant first reported a position in Arbutus Biopharma in Q4 2021 and held it in 1 quarter.
First Quadrant's Arbutus Biopharma position peaked at $294K in Q4 2021.
119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.